Relay Therapeutics CFO sells shares for tax withholding
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Relay Therapeutics, Inc. Chief Financial Officer Thomas Catinazzo reported the sale of 1,459 shares of common stock on July 28, 2026 at $18.61 per share. The shares were sold solely to cover income tax withholding from the vesting of 3,269 RSUs, with no discretion by the officer and in line with company policies. After the sale, he beneficially owns 158,285 shares, including 6,538 shares underlying RSUs.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock F1, F2 | 1,459 | $18.61 | $27K |
Footnotes (2)
- F1. Sale of shares to cover the reporting person's income tax withholding obligations upon the vesting of 3,269 shares of restricted stock units ("RSUs") on July 27, 2026. The reporting person had no discretion with respect to such sale, which was transacted in accordance with the Issuer's policies regarding the vesting of RSUs.
- F2. Includes 6,538 shares underlying RSUs.
Key Figures
Key Terms
restricted stock units financial
income tax withholding obligations financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Relay Therapeutics (RLAY) CFO Thomas Catinazzo report in this Form 4?
What RSU activity for Relay Therapeutics (RLAY) is disclosed for the CFO?
AI-generated analysis. How Rhea-AI works. Not financial advice.